Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 204


Concomitant loss of EAF2/U19 and Pten synergistically promotes prostate carcinogenesis in the mouse model.

Ai J, Pascal LE, O'Malley KJ, Dar JA, Isharwal S, Qiao Z, Ren B, Rigatti LH, Dhir R, Xiao W, Nelson JB, Wang Z.

Oncogene. 2014 May 1;33(18):2286-94. doi: 10.1038/onc.2013.190. Epub 2013 May 27.


Development of a reactive stroma associated with prostatic intraepithelial neoplasia in EAF2 deficient mice.

Pascal LE, Ai J, Masoodi KZ, Wang Y, Wang D, Eisermann K, Rigatti LH, O'Malley KJ, Ma HM, Wang X, Dar JA, Parwani AV, Simons BW, Ittman MM, Li L, Davies BJ, Wang Z.

PLoS One. 2013 Nov 18;8(11):e79542. doi: 10.1371/journal.pone.0079542. eCollection 2013.


Loss of Nkx3.1 leads to the activation of discrete downstream target genes during prostate tumorigenesis.

Song H, Zhang B, Watson MA, Humphrey PA, Lim H, Milbrandt J.

Oncogene. 2009 Sep 17;28(37):3307-19. doi: 10.1038/onc.2009.181. Epub 2009 Jul 13.


U19/Eaf2 knockout causes lung adenocarcinoma, B-cell lymphoma, hepatocellular carcinoma and prostatic intraepithelial neoplasia.

Xiao W, Zhang Q, Habermacher G, Yang X, Zhang AY, Cai X, Hahn J, Liu J, Pins M, Doglio L, Dhir R, Gingrich J, Wang Z.

Oncogene. 2008 Mar 6;27(11):1536-44. Epub 2007 Sep 17.


Inhibition of 5alpha-reductase enhances testosterone-induced expression of U19/Eaf2 tumor suppressor during the regrowth of LNCaP xenograft tumor in nude mice.

Gupta S, Wang Y, Ramos-Garcia R, Shevrin D, Nelson JB, Wang Z.

Prostate. 2010 Oct 1;70(14):1575-85. doi: 10.1002/pros.21193.


EAF2 loss enhances angiogenic effects of Von Hippel-Lindau heterozygosity on the murine liver and prostate.

Pascal LE, Ai J, Rigatti LH, Lipton AK, Xiao W, Gnarra JR, Wang Z.

Angiogenesis. 2011 Sep;14(3):331-43. doi: 10.1007/s10456-011-9217-1. Epub 2011 Jun 3.


PTEN deficiency is fully penetrant for prostate adenocarcinoma in C57BL/6 mice via mTOR-dependent growth.

Blando J, Portis M, Benavides F, Alexander A, Mills G, Dave B, Conti CJ, Kim J, Walker CL.

Am J Pathol. 2009 May;174(5):1869-79. doi: 10.2353/ajpath.2009.080055.


Conditional deletion of the Pten gene in the mouse prostate induces prostatic intraepithelial neoplasms at early ages but a slow progression to prostate tumors.

Kwak MK, Johnson DT, Zhu C, Lee SH, Ye DW, Luong R, Sun Z.

PLoS One. 2013;8(1):e53476. doi: 10.1371/journal.pone.0053476. Epub 2013 Jan 8.


Klf5 deletion promotes Pten deletion-initiated luminal-type mouse prostate tumors through multiple oncogenic signaling pathways.

Xing C, Ci X, Sun X, Fu X, Zhang Z, Dong EN, Hao ZZ, Dong JT.

Neoplasia. 2014 Nov 20;16(11):883-99. doi: 10.1016/j.neo.2014.09.006. eCollection 2014 Nov.


Pirin down-regulates the EAF2/U19 protein and alleviates its growth inhibition in prostate cancer cells.

Qiao Z, Wang D, Hahn J, Ai J, Wang Z.

Prostate. 2014 Feb;74(2):113-20. doi: 10.1002/pros.22729. Epub 2013 Nov 23.


Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis.

Ma X, Ziel-van der Made AC, Autar B, van der Korput HA, Vermeij M, van Duijn P, Cleutjens KB, de Krijger R, Krimpenfort P, Berns A, van der Kwast TH, Trapman J.

Cancer Res. 2005 Jul 1;65(13):5730-9.


Assessing the order of critical alterations in prostate cancer development and progression by IHC: further evidence that PTEN loss occurs subsequent to ERG gene fusion.

Gumuskaya B, Gurel B, Fedor H, Tan HL, Weier CA, Hicks JL, Haffner MC, Lotan TL, De Marzo AM.

Prostate Cancer Prostatic Dis. 2013 Jun;16(2):209-15. doi: 10.1038/pcan.2013.8. Epub 2013 Apr 2.


Tumor suppressor U19/EAF2 regulates thrombospondin-1 expression via p53.

Su F, Pascal LE, Xiao W, Wang Z.

Oncogene. 2010 Jan 21;29(3):421-31. doi: 10.1038/onc.2009.326. Epub 2009 Oct 12.


The pace of prostatic intraepithelial neoplasia development is determined by the timing of Pten tumor suppressor gene excision.

Luchman HA, Benediktsson H, Villemaire ML, Peterson AC, Jirik FR.

PLoS One. 2008;3(12):e3940. doi: 10.1371/journal.pone.0003940. Epub 2008 Dec 15.


Plumbagin Inhibits Prostate Carcinogenesis in Intact and Castrated PTEN Knockout Mice via Targeting PKCĪµ, Stat3, and Epithelial-to-Mesenchymal Transition Markers.

Hafeez BB, Fischer JW, Singh A, Zhong W, Mustafa A, Meske L, Sheikhani MO, Verma AK.

Cancer Prev Res (Phila). 2015 May;8(5):375-86. doi: 10.1158/1940-6207.CAPR-14-0231. Epub 2015 Jan 27.


Loss of survivin in the prostate epithelium impedes carcinogenesis in a mouse model of prostate adenocarcinoma.

Adisetiyo H, Liang M, Liao CP, Aycock-Williams A, Cohen MB, Xu S, Neamati N, Conway EM, Cheng CY, Nikitin AY, Roy-Burman P.

PLoS One. 2013 Jul 31;8(7):e69484. doi: 10.1371/journal.pone.0069484. Print 2013.


Id4 deficiency attenuates prostate development and promotes PIN-like lesions by regulating androgen receptor activity and expression of NKX3.1 and PTEN.

Sharma P, Knowell AE, Chinaranagari S, Komaragiri S, Nagappan P, Patel D, Havrda MC, Chaudhary J.

Mol Cancer. 2013 Jun 21;12:67. doi: 10.1186/1476-4598-12-67.


The influence of growth hormone/insulin-like growth factor deficiency on prostatic dysplasia in pbARR2-Cre, PTEN knockout mice.

Takahara K, Ibuki N, Ghaffari M, Tearle H, Ong CJ, Azuma H, Gleave ME, Pollak M, Cox ME.

Prostate Cancer Prostatic Dis. 2013 Sep;16(3):239-47. doi: 10.1038/pcan.2013.14. Epub 2013 May 21.


A mouse model of heterogeneous, c-MYC-initiated prostate cancer with loss of Pten and p53.

Kim J, Roh M, Doubinskaia I, Algarroba GN, Eltoum IE, Abdulkadir SA.

Oncogene. 2012 Jan 19;31(3):322-32. doi: 10.1038/onc.2011.236. Epub 2011 Jun 20.


Loss of ATF3 promotes Akt activation and prostate cancer development in a Pten knockout mouse model.

Wang Z, Xu D, Ding HF, Kim J, Zhang J, Hai T, Yan C.

Oncogene. 2015 Sep 17;34(38):4975-84. doi: 10.1038/onc.2014.426. Epub 2014 Dec 22.

Supplemental Content

Support Center